Theravance Biopharma (TBPH) Other Non-Current Assets (2014 - 2026)

Theravance Biopharma (TBPH) has 13 years of Other Non-Current Assets data on file, last reported at $25.3 million in Q1 2026.

• Other Non-Current Assets for Q1 2026 came in at $25.3 million, up 2926.67% year-over-year; the trailing twelve-month figure through Mar 2026 was $25.3 million (up 2926.67% YoY), and the FY2025 annual result was $24.9 million, up 102.51% from the prior year.
• Other Non-Current Assets grew to $25.3 million in Q1 2026 per TBPH's latest filing, from $24.9 million in the prior quarter.
• Over five years, Other Non-Current Assets peaked at $25.3 million in Q1 2026 and troughed at $836000.0 in Q3 2022.
• A 5-year average of $9.5 million and a median of $7.7 million in 2024 frame the typical range for Other Non-Current Assets.
• The sharpest annual moves came in 2024 and 2026: Other Non-Current Assets slumped 93.09% in 2024, then jumped 2926.67% in 2026.
• A 5-year view of Other Non-Current Assets shows it stood at $6.9 million in 2022, then rose by 16.93% to $8.1 million in 2023, then soared by 52.3% to $12.3 million in 2024, then surged by 102.51% to $24.9 million in 2025, then increased by 1.7% to $25.3 million in 2026.
• Business Quant data shows TBPH's Other Non-Current Assets at $25.3 million in Q1 2026, $24.9 million in Q4 2025, and $25.2 million in Q3 2025.